Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Gains from Investment Securities: 2016-2025

Historic Gains from Investment Securities for Tg Therapeutics (TGTX) over the last 9 years, with Sep 2025 value amounting to $2.0 million.

  • Tg Therapeutics' Gains from Investment Securities was N/A to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year change of. This contributed to the annual value of $4.5 million for FY2024, which is 4.83% down from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Gains from Investment Securities is $2.0 million, which was down 52.00% from $4.1 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Gains from Investment Securities high stood at $4.7 million for Q1 2024, and its period low was -$8.1 million during Q4 2021.
  • Over the past 3 years, Tg Therapeutics' median Gains from Investment Securities value was $1.2 million (recorded in 2024), while the average stood at $2.0 million.
  • Examining YoY changes over the last 5 years, Tg Therapeutics' Gains from Investment Securities showed a top increase of 1,609.13% in 2021 and a maximum decrease of 947.87% in 2021.
  • Tg Therapeutics' Gains from Investment Securities (Quarterly) stood at -$8.1 million in 2021, then spiked by 72.94% to -$2.2 million in 2022, then spiked by 33.20% to -$1.5 million in 2023, then spiked by 133.94% to $500,000 in 2024, then declined by 12.65% to $2.0 million in 2025.
  • Its Gains from Investment Securities stands at $2.0 million for Q3 2025, versus $4.1 million for Q2 2025 and $4.5 million for Q1 2025.